Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

Trial Details

NCT ID

NCT05096390

Phase

PHASE2

Sponsor

Centre Leon Berard

Status

RECRUITING

Cancer Type

Papillary Renal Cell Carcinoma Kidney Cancer

Interventions

• Axitinib Oral Tablet [Inlyta]
• Pembrolizumab Injection [Keytruda]

Locations (sample)

• Angers, France|47.47156,-0.55202
• Besançon, France|47.24878,6.01815
• Bordeaux, France|44.84124,-0.58046
• Clermont-Ferrand, France|45.77969,3.08682
• Lyon, France|45.74906,4.84789

Key Eligibility Criteria

• Age ≥ 18 years on the day of signing informed consent.
• Metastatic or locally advanced (inoperable) type 2 or mixed PRCC, histologically confirmed by central review: FFPE blocks (or all HES and IHC slide…
• No prior systemic treatment for renal cancer (chemotherapy, immunotherapy, anti-angiogenic drugs, or treatment under evaluation) even in adjuvant s…
• At least one measurable site of disease according to RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.